> top > docs > PubMed:27028795 > annotations

PubMed:27028795 JSONTXT

Annnotations TAB JSON ListView MergeView

Preeclampsia

Id Subject Object Predicate Lexical cue
PD-Preeclampsia-B_T1 55-67 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T2 289-301 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T3 426-438 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T4 2053-2065 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T5 2378-2390 ORPHA:275555 denotes preeclampsia

Preeclampsia-compare

Id Subject Object Predicate Lexical cue
PD-Preeclampsia-B_T1 55-67 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T2 289-301 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T3 426-438 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T4 2053-2065 ORPHA:275555 denotes preeclampsia
PD-Preeclampsia-B_T5 2378-2390 ORPHA:275555 denotes preeclampsia

preeclampsia_genes

Id Subject Object Predicate Lexical cue
PD-PreeclampsiaGenes-B_T1 165-180 HGNC:TYK2 denotes tyrosine kinase
PD-PreeclampsiaGenes-B_T2 195-218 HGNC:PGF denotes placental growth factor

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-93 Sentence denotes KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
TextSentencer_T2 94-104 Sentence denotes OBJECTIVE:
TextSentencer_T3 105-302 Sentence denotes To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia.
TextSentencer_T4 303-311 Sentence denotes METHODS:
TextSentencer_T5 312-439 Sentence denotes We studied 412 women carrying a singleton pregnancy from a previous study cohort who were evaluated for suspected preeclampsia.
TextSentencer_T6 440-559 Sentence denotes Another 434 nonpreeclamptic patients with plasma samples drawn throughout pregnancy were used to derive normative data.
TextSentencer_T7 560-724 Sentence denotes Plasma sFlt1 and PlGF levels were measured on the automated KRYPTOR platform and evaluated for prediction of adverse maternal and perinatal outcomes within 2 weeks.
TextSentencer_T8 725-885 Sentence denotes Normative values were used to create a ratio of markers and these values were reported as multiples of median (MoM) for women with and without adverse outcomes.
TextSentencer_T9 886-1015 Sentence denotes The KRYPTOR assay results were also compared with previously reported measurements obtained using the automated Elecsys platform.
TextSentencer_T10 1016-1024 Sentence denotes RESULTS:
TextSentencer_T11 1025-1438 Sentence denotes Among participants presenting at <34 weeks (N = 110), patients with subsequent adverse outcome had higher sFlt1, lower PlGF, and higher sFlt1/PlGF ratio compared with women without adverse outcomes: the median (25th, 75th centile) sFlt1 (pg/ml), 9030 (3197, 12,140) versus 1976 (1248, 2937); PlGF (pg/ml), 36 (16, 111) versus 318 (108, 629); and ratio, 285.6 (32.2, 758.5) versus 6.1 (2.3, 20.3) (all p < 0.0001).
TextSentencer_T12 1439-1708 Sentence denotes Higher sFlt1/PlGF ratio correlated negatively with timing of delivery (r = -0.60, p < 0.001) and the risk of adverse outcomes was markedly elevated among women in highest tertile compared with lower tertile (odds ratio, 14.77; 95% confidence interval (CI), 4.28-51.00).
TextSentencer_T13 1709-1869 Sentence denotes The addition of sFlt1/PlGF ratio (≥85) to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (AUC 0.89 (95% CI):
TextSentencer_T14 1870-1989 Sentence denotes 0.82, 0.95) for hypertension, proteinuria, and sFlt1/PlGF (AUC = 0.75 (0.65, 0.85)) for hypertension alone (p = 0.002).
TextSentencer_T15 1990-2340 Sentence denotes Compared with normative controls, women who were evaluated for preeclampsia without adverse outcomes had higher MoM for sFlt1/PlGF ratio; these values were further elevated in women with adverse outcomes. sFlt1/PlGF ratios measured on the KRYPTOR platform were highly correlated with measurements obtained using Elecys platform (r = 0.97, p < 0.001).
TextSentencer_T16 2341-2353 Sentence denotes CONCLUSIONS:
TextSentencer_T17 2354-2655 Sentence denotes In women with suspected preeclampsia presenting prior to 34 weeks of gestation, KRYPTOR assays for circulating sFlt1 and PlGF when used in conjunction with standard clinical evaluation performs well in the prediction of adverse maternal and perinatal outcomes occurring within 2 weeks of presentation.
T1 0-93 Sentence denotes KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
T2 94-104 Sentence denotes OBJECTIVE:
T3 105-302 Sentence denotes To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia.
T4 303-311 Sentence denotes METHODS:
T5 312-439 Sentence denotes We studied 412 women carrying a singleton pregnancy from a previous study cohort who were evaluated for suspected preeclampsia.
T6 440-559 Sentence denotes Another 434 nonpreeclamptic patients with plasma samples drawn throughout pregnancy were used to derive normative data.
T7 560-724 Sentence denotes Plasma sFlt1 and PlGF levels were measured on the automated KRYPTOR platform and evaluated for prediction of adverse maternal and perinatal outcomes within 2 weeks.
T8 725-885 Sentence denotes Normative values were used to create a ratio of markers and these values were reported as multiples of median (MoM) for women with and without adverse outcomes.
T9 886-1015 Sentence denotes The KRYPTOR assay results were also compared with previously reported measurements obtained using the automated Elecsys platform.
T10 1016-1024 Sentence denotes RESULTS:
T11 1025-1438 Sentence denotes Among participants presenting at <34 weeks (N = 110), patients with subsequent adverse outcome had higher sFlt1, lower PlGF, and higher sFlt1/PlGF ratio compared with women without adverse outcomes: the median (25th, 75th centile) sFlt1 (pg/ml), 9030 (3197, 12,140) versus 1976 (1248, 2937); PlGF (pg/ml), 36 (16, 111) versus 318 (108, 629); and ratio, 285.6 (32.2, 758.5) versus 6.1 (2.3, 20.3) (all p < 0.0001).
T12 1439-1708 Sentence denotes Higher sFlt1/PlGF ratio correlated negatively with timing of delivery (r = -0.60, p < 0.001) and the risk of adverse outcomes was markedly elevated among women in highest tertile compared with lower tertile (odds ratio, 14.77; 95% confidence interval (CI), 4.28-51.00).
T13 1709-1869 Sentence denotes The addition of sFlt1/PlGF ratio (≥85) to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (AUC 0.89 (95% CI):
T14 1870-1989 Sentence denotes 0.82, 0.95) for hypertension, proteinuria, and sFlt1/PlGF (AUC = 0.75 (0.65, 0.85)) for hypertension alone (p = 0.002).
T15 1990-2340 Sentence denotes Compared with normative controls, women who were evaluated for preeclampsia without adverse outcomes had higher MoM for sFlt1/PlGF ratio; these values were further elevated in women with adverse outcomes. sFlt1/PlGF ratios measured on the KRYPTOR platform were highly correlated with measurements obtained using Elecys platform (r = 0.97, p < 0.001).
T16 2341-2353 Sentence denotes CONCLUSIONS:
T17 2354-2655 Sentence denotes In women with suspected preeclampsia presenting prior to 34 weeks of gestation, KRYPTOR assays for circulating sFlt1 and PlGF when used in conjunction with standard clinical evaluation performs well in the prediction of adverse maternal and perinatal outcomes occurring within 2 weeks of presentation.

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 195-204 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placental